Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, PD and Food Effect of WD-910 in Healthy Participants
NCT06897813Phase 1Not yet recruiting
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS), Dementia and Alzheimer's disease (AD) comparing WD-910 with Placebo (2 arms). Primary endpoints: Incidence of adverse events (AEs), Number of participants with abnormal lab values and 10 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
WD-910
03
Conditions
multiple sclerosis (MS)DementiaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06897813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897813.